A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
Pharmacology, Toxicology and Pharmaceutical Science
2
4%
Nursing and Health Professions
2
4%
Agricultural and Biological Sciences
2
4%
Computer Science
2
4%
Other
3
6%
Unknown
33
65%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 March 2021.
All research outputs
#22,774,430
of 25,387,668 outputs
Outputs from ESMO Open
#1,015
of 1,152 outputs
Outputs of similar age
#392,663
of 453,142 outputs
Outputs of similar age from ESMO Open
#57
of 61 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,152 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 453,142 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.